Results 41 to 50 of about 5,080 (193)

Navigating the Prescription Drug Information System

Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 855-870, October 2026.
Information on new prescription drugs is increasingly complex and fragmented, posing challenges for healthcare professionals, patients, and payers. Clinicians require concise, actionable guidance to support prescribing decisions, while patients seek to balance benefits and harms when making decisions aligned with their treatment goals.
Irina V. Wang, Courtney Davis, Robin Forrest, Avi Cherla, Maximilian Siebert, Janice Cowden, Sophia Walker, Tamar Krishnamurti, Florence T. Bourgeois, Steven Woloshin, Anita K. Wagner, Huseyin Naci   +11 more
wiley   +1 more source

The anti-amyloid monoclonal antibody Lecanemab: 16 cautionary notes [PDF]

, 2023
The recent CLARITY AD results for the monoclonal anti-amyloid antibody Lecanemab have been interpreted as promising, supporting the amyloid hypothesis of Alzheimer’s disease and leading to consideration for approval by the Food and Drug Administration ...
Høilund-Carlsen, Poul F, Espay, Alberto J, Herrup, Karl, Sensi, Stefano L, Alavi, Abass, Vissel, Bryce, Perry, George, Johnsen, Kasper B., Neve, Rachael L., Kepp, Kasper P., Barrio, Jorge R, Barrio, Jorge R., Neve, Rachael L, Robakis, Nikolaos K, Høilund-Carlsen, Poul F., Kepp, Kasper P, Sensi, Stefano L., Espay, Alberto J., Johnsen, Kasper B, Robakis, Nikolaos K.   +19 more
core   +1 more source

Predicting Relevant Microglia‐Associated Cell–Cell Communication Pathways in Alzheimer's Disease: A Role for SPP1

Glia, Volume 74, Issue 10, October 2026.
We used CellChat to infer altered cell–cell communication in Alzheimer's disease Microglia signal to each other via SPP1 in Alzheimer's disease. SPP1‐expressing microglia are present around amyloid‐β plaques. ABSTRACT Microglia play a key role in the pathophysiology of Alzheimer's Disease (AD) and their increased heterogeneity likely affects disease ...
Janssen M. Kotah, Marina Trombetta Lima, Esmée C. Dragt, Asimenia Voulgaroglou, Nieske Brouwer, Inge R. Holtman, Susanne M. Kooistra, Bart J. L. Eggen   +7 more
wiley   +1 more source

Alzheimer's Disease Beyond Amyloid: Lessons From Atherosclerosis

Annals of Clinical and Translational Neurology, EarlyView.
Marcello Ciaccio, Luisa Agnello
wiley   +1 more source

The Crosstalk Between Diabetes and Alzheimer's Disease: A Molecular Perspective

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 4, October 2026.
Increasing evidence indicates an association between type 2 diabetes mellitus and Alzheimer’s disease, contributing to the proposed concept of AD as “type 3 diabetes.” Shared biological features such as impaired insulin signaling, chronic inflammation, mitochondrial dysfunction, and oxidative stress have been observed in both T2DM and AD.
Deniz Catakli, Ozlem Ozen‐Basoglu, Ebru Busra Tuncgovde, Gonen Ozsarlak‐Sozer   +3 more
wiley   +1 more source

Real‐world experience with lecanemab therapy for Alzheimer's disease in the Intermountain West

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION Lecanemab is a monoclonal antibody targeting amyloid plaques that has been approved for the treatment of early symptomatic Alzheimer's disease.
Bethany C. Curd, Camilla Zubrick, Christine J. Cliatt Brown, Michelle Keown Sorweid, Sarah B. Dehoney, Yoshimi Anzai, Satoshi Minoshima, Anna L. Parks, Nicholas A. Frost   +8 more
doaj   +1 more source

Mitochondria‐Targeted Nanotherapies in Aging Neurodegenerative Disorders: Emerging Prospects and Clinical Potential

Advanced Healthcare Materials, Volume 15, Issue 36, 25 September 2026.
Mitochondria‐targeted nanotherapies emerge as a promising strategy for combating aging‐associated neurodegenerative disorders (NDs) by restoring mitochondrial function, reducing oxidative stress, and improving neuronal survival. Recent advances in nanotechnology, therapeutic delivery, and translational research are highlighted, providing insights into ...
Dnyandev G. Gadhave, Ashish B. Jadhav, Nitin B. Waghamode, Shubham Khot, Rajiya Khan, Ravi Hole, Shankar M. Dhobale, Manoj Aswar, Keshav Raj Paudel   +8 more
wiley   +1 more source

More efficient screening for preclinical Alzheimer's clinical trials using mixture of experts

Alzheimer's &Dementia, Volume 22, Issue 9, September 2026.
Abstract INTRODUCTION Blood plasma biomarkers identifying Alzheimer's disease (AD) neuropathology offer accessible and scalable alternatives to lumbar puncture and positron emission tomography (PET) scans, with potential efficiency gains in clinical trial recruitment.
Oliver Langford, Rema Raman, Paul Aisen, Reisa Sperling, Keith Johnson, Doris Molina‐Henry, Pallavi Sachdev, David Li, Gustavo A. Jimenez‐Maggiora, Sterling C. Johnson, Joel B Braunstein, Colin Birkenbihl, Madison Cuppels, Rachel F. Buckley, Robert A. Rissman, Michael C. Donohue   +15 more
wiley   +1 more source

Comparison of safety of lecanemab and aducanumab: a real-world disproportionality analysis using the FDA adverse event reporting system

Frontiers in Pharmacology
ObjectiveStudies on anti-Aβ drugs for the treatment of Alzheimer’s disease (AD) have garnered significant attention; however, their safety still requires further research and monitoring. Although recent studies have analyzed the adverse drug events (ADEs)
Lingti Kong, Lingti Kong, Lingti Kong, Xiaohu Yang, Xiaohu Yang, Jian Xu, Jian Xu   +6 more
doaj   +1 more source

Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease

CPT: Pharmacometrics & Systems Pharmacology, 2022
Lecanemab is a humanized immunoglobulin G1 monoclonal antibody that selectively binds to soluble Aβ aggregate species, while demonstrating low affinity for Aβ monomer. This article describes the population pharmacokinetic (PK) and PK/pharmacodynamic (PD)
Seiichi Hayato, Osamu Takenaka, Sree Harsha Sreerama Reddy, Ishani Landry, Larisa Reyderman, Akihiko Koyama, Chad Swanson, Sanae Yasuda, Ziad Hussein   +8 more
doaj   +1 more source